Diabetic Cardiomyopathy - Pipeline Insight, 2021
This report can be delivered to the clients within 48-72 Hours
DelveInsight’s, “Diabetic Cardiomyopathy - Pipeline Insight, 2021,” report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Diabetic Cardiomyopathy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Diabetic Cardiomyopathy: Overview
Diabetic cardiomyopathy is a type of cardiovascular damage present in patients suffering from diabetes. It is characterized by myocardial dilatation and hypertrophy as well as a decrease in the systolic and diastolic functions of the left ventricle, and its presence is independent of the coexistence of ischemic heart disease or hypertension. Existence of this condition in a diabetic patient may have several therapeutic implications including: improving glycemic control, earlier use of calcium channel blockers (CCBs), ACE inhibitors and ARBs, exercise training, lipid-lowering therapy, and antioxidant and insulin-sensitizing drugs. Increasing evidence suggests that hyperglycemia is central to the pathogenesis of diabetic cardiomyopathy, which triggers a series of maladaptive events leading to cardiomyocyte apoptosis, collagen deposition, and cardiac fibrosis.
“Diabetic Cardiomyopathy - Pipeline Insight, 2021” report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Diabetic Cardiomyopathy pipeline landscape is provided which includes the disease overview and Diabetic Cardiomyopathy treatment guidelines. The assessment part of the report embraces, in depth Diabetic Cardiomyopathy commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Diabetic Cardiomyopathy collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence Diabetic Cardiomyopathy R&D. The therapies under development are focused on novel approaches to treat/improve Diabetic Cardiomyopathy.
Diabetic Cardiomyopathy Emerging Drugs Chapters
This segment of the Diabetic Cardiomyopathy report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Diabetic Cardiomyopathy Emerging Drugs
IMB-1018972: Imbria Pharmaceuticals
Mechanism of Action: Partial fatty acid oxidation inhibitors. Currently under phase 2 of clinical trials for the treatment of diabetic cardiaomyopathy
AT-001: Applied Therapeutics
AT-001 is an investigational, novel Aldose Reductase Inhibitor (ARI) being developed as an oral therapy for the treatment of Diabetic Cardiomyopathy (DbCM). Applied Therapeutics initiated a Phase 3 registrational study in DbCM with this potent and selective agent in September 2019.
Further product details are provided in the report……..
Diabetic Cardiomyopathy: Therapeutic Assessment
This segment of the report provides insights about the different Diabetic Cardiomyopathy drugs segregated based on following parameters that define the scope of the report, such as:
Major Players in Diabetic Cardiomyopathy
There are approx. 3+ key companies which are developing the therapies for Diabetic Cardiomyopathy. The companies which have their Diabetic Cardiomyopathy drug candidates in the mid to advanced stage, i.e. phase II include, Imbria Pharmaceuticals and others.
Phases
DelveInsight’s report covers around 3+ products under different phases of clinical development like
Diabetic Cardiomyopathy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Diabetic Cardiomyopathy: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Diabetic Cardiomyopathy therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Diabetic Cardiomyopathy drugs.
Diabetic Cardiomyopathy Report Insights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “Diabetic Cardiomyopathy - Pipeline Insight, 2021,” report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Diabetic Cardiomyopathy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Diabetic Cardiomyopathy: Overview
Diabetic cardiomyopathy is a type of cardiovascular damage present in patients suffering from diabetes. It is characterized by myocardial dilatation and hypertrophy as well as a decrease in the systolic and diastolic functions of the left ventricle, and its presence is independent of the coexistence of ischemic heart disease or hypertension. Existence of this condition in a diabetic patient may have several therapeutic implications including: improving glycemic control, earlier use of calcium channel blockers (CCBs), ACE inhibitors and ARBs, exercise training, lipid-lowering therapy, and antioxidant and insulin-sensitizing drugs. Increasing evidence suggests that hyperglycemia is central to the pathogenesis of diabetic cardiomyopathy, which triggers a series of maladaptive events leading to cardiomyocyte apoptosis, collagen deposition, and cardiac fibrosis.
“Diabetic Cardiomyopathy - Pipeline Insight, 2021” report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Diabetic Cardiomyopathy pipeline landscape is provided which includes the disease overview and Diabetic Cardiomyopathy treatment guidelines. The assessment part of the report embraces, in depth Diabetic Cardiomyopathy commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Diabetic Cardiomyopathy collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence Diabetic Cardiomyopathy R&D. The therapies under development are focused on novel approaches to treat/improve Diabetic Cardiomyopathy.
Diabetic Cardiomyopathy Emerging Drugs Chapters
This segment of the Diabetic Cardiomyopathy report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Diabetic Cardiomyopathy Emerging Drugs
IMB-1018972: Imbria Pharmaceuticals
Mechanism of Action: Partial fatty acid oxidation inhibitors. Currently under phase 2 of clinical trials for the treatment of diabetic cardiaomyopathy
AT-001: Applied Therapeutics
AT-001 is an investigational, novel Aldose Reductase Inhibitor (ARI) being developed as an oral therapy for the treatment of Diabetic Cardiomyopathy (DbCM). Applied Therapeutics initiated a Phase 3 registrational study in DbCM with this potent and selective agent in September 2019.
Further product details are provided in the report……..
Diabetic Cardiomyopathy: Therapeutic Assessment
This segment of the report provides insights about the different Diabetic Cardiomyopathy drugs segregated based on following parameters that define the scope of the report, such as:
Major Players in Diabetic Cardiomyopathy
There are approx. 3+ key companies which are developing the therapies for Diabetic Cardiomyopathy. The companies which have their Diabetic Cardiomyopathy drug candidates in the mid to advanced stage, i.e. phase II include, Imbria Pharmaceuticals and others.
Phases
DelveInsight’s report covers around 3+ products under different phases of clinical development like
- Late-stage products (Phase III)
- Mid-stage products (Phase II and Phase I/II)
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
Diabetic Cardiomyopathy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Subcutaneous
- Intravenous
- Oral
- Intramuscular
- Molecule Type
- Small molecules
- Natural metabolites
- Monoclonal antibodies
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Diabetic Cardiomyopathy: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Diabetic Cardiomyopathy therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Diabetic Cardiomyopathy drugs.
Diabetic Cardiomyopathy Report Insights
- Diabetic Cardiomyopathy Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Diabetic Cardiomyopathy drugs?
- How many Diabetic Cardiomyopathy drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Diabetic Cardiomyopathy?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Diabetic Cardiomyopathy therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Diabetic Cardiomyopathy and their status?
- What are the key designations that have been granted to the emerging drugs?
- Imbria Pharmaceuticals
- Applied Therapeutics
- IMB-1018972
- AT-001
Introduction
Executive Summary
Diabetic Cardiomyopathy: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Diabetic Cardiomyopathy – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Diabetic Cardiomyopathy companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Diabetic Cardiomyopathy Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
AT-001: Applied Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
IMB-101897: Imbria Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Diabetic Cardiomyopathy Key Companies
Diabetic Cardiomyopathy Key Products
Diabetic Cardiomyopathy- Unmet Needs
Diabetic Cardiomyopathy- Market Drivers and Barriers
Diabetic Cardiomyopathy- Future Perspectives and Conclusion
Diabetic Cardiomyopathy Analyst Views
Diabetic Cardiomyopathy Key Companies
Appendix
Executive Summary
Diabetic Cardiomyopathy: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Diabetic Cardiomyopathy – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Diabetic Cardiomyopathy companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Diabetic Cardiomyopathy Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
AT-001: Applied Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
IMB-101897: Imbria Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Diabetic Cardiomyopathy Key Companies
Diabetic Cardiomyopathy Key Products
Diabetic Cardiomyopathy- Unmet Needs
Diabetic Cardiomyopathy- Market Drivers and Barriers
Diabetic Cardiomyopathy- Future Perspectives and Conclusion
Diabetic Cardiomyopathy Analyst Views
Diabetic Cardiomyopathy Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Diabetic Cardiomyopathy
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Diabetic Cardiomyopathy
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Diabetic Cardiomyopathy
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Diabetic Cardiomyopathy
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
